CA2362970A1 - Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy - Google Patents

Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy Download PDF

Info

Publication number
CA2362970A1
CA2362970A1 CA002362970A CA2362970A CA2362970A1 CA 2362970 A1 CA2362970 A1 CA 2362970A1 CA 002362970 A CA002362970 A CA 002362970A CA 2362970 A CA2362970 A CA 2362970A CA 2362970 A1 CA2362970 A1 CA 2362970A1
Authority
CA
Canada
Prior art keywords
hormone
nucleic acid
factor
hre
progesterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362970A
Other languages
English (en)
French (fr)
Inventor
Charlotte Hauser-Funke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octagene GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107099 external-priority patent/DE19907099A1/de
Application filed by Individual filed Critical Individual
Publication of CA2362970A1 publication Critical patent/CA2362970A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002362970A 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy Abandoned CA2362970A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12084899P 1999-02-19 1999-02-19
DE1999107099 DE19907099A1 (de) 1999-02-19 1999-02-19 Hormon-Hormonrezeptorkomplexe und Nukleinsäurekonstrukte und ihre Verwendung in der Gentherapie
DE19907099.7 1999-02-19
US60/120,848 1999-02-19
PCT/EP2000/001368 WO2000049147A1 (en) 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Publications (1)

Publication Number Publication Date
CA2362970A1 true CA2362970A1 (en) 2000-08-24

Family

ID=26051947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362970A Abandoned CA2362970A1 (en) 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Country Status (6)

Country Link
EP (1) EP1151099A1 (ja)
JP (1) JP2002537311A (ja)
AU (2) AU780854B2 (ja)
CA (1) CA2362970A1 (ja)
NZ (1) NZ513595A (ja)
WO (1) WO2000049147A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5247400A (en) * 1999-06-14 2001-01-02 Chisso Corporation Substance binding to the substrate of activated blood coagulation factor in competition with this factorto thereby regulate the r eaction between the activated blood coagulation factor and the substrate, a process for producing the substance and blood coagulation
EP1136553A1 (en) * 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
MXPA02009221A (es) * 2000-03-22 2005-07-25 Octagene Gmbh Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas.
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
WO2002028175A2 (en) * 2000-10-03 2002-04-11 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Transgenic mouse for targeted recombination mediated by modified cre-er
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20020197670A1 (en) * 2001-06-22 2002-12-26 Price Thomas M. Membrane associated progesterone receptor
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
AU6087694A (en) * 1993-01-26 1994-08-15 Research Institute of the Palo Alto Medical Foundation, The The l-plastin promoter region and its uses
WO1994018172A1 (en) * 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Imidazolylbenzene compound and use thereof as medicine
US5512483A (en) * 1993-05-21 1996-04-30 Mcgill University Expression vectors responsive to steroid hormones
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie

Also Published As

Publication number Publication date
AU2005200908A1 (en) 2005-03-24
JP2002537311A (ja) 2002-11-05
WO2000049147A1 (en) 2000-08-24
AU780854B2 (en) 2005-04-21
NZ513595A (en) 2001-09-28
AU2806100A (en) 2000-09-04
EP1151099A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
CN108570479B (zh) 一种基于CRISPR/Cas9技术介导绒山羊VEGF基因定点敲入的方法
KR102390075B1 (ko) 오르니틴 트랜스카르바밀라아제（ｏｔｃ） 결핍증의 치료에 유용한 조성물
AU707684B2 (en) Modified nuclear glucocorticoid receptor, fusion protein, and DNA fragments coding for said receptor and said fusion protein
Feil et al. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains
AU2024205047A1 (en) Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
US6825396B2 (en) Methods for tissue specific synthesis of protein in eggs of transgenic hens
AU2020289750A1 (en) Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
CN112375748B (zh) 基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用
KR20180086266A (ko) 척수성 근위축증의 치료에 유용한 아데노-관련 바이러스 벡터
CZ28099A3 (cs) Transkripční regulační DNA z křeččího EF-1alfa
CN112941038B (zh) 基于水疱性口炎病毒载体的重组新型冠状病毒及其制备方法与应用
AU2005200908A1 (en) Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
CN112251464B (zh) 一种基因点突变的诱导方法
CN114728173A (zh) 用于配体依赖性转录调控的具有异源停止转移序列的新型受体
US20030145345A1 (en) LexA DNA binding domain optimized for arabidopsis species
CN113166779A (zh) 调控的基因编辑系统
KR102027400B1 (ko) 정의된 항원에 대한 보호 체액성 면역 반응을 형성하는 재조합 효모를 이용한 예방 접종
US20040068762A1 (en) Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
TW202302857A (zh) 多臂黏液瘤(myxoma)病毒
CN106978445A (zh) CRISPER‑Cas9系统介导的山羊EDAR基因敲除的方法
US6524850B1 (en) Kinase wee1 fusion protein compositions, nucleotide sequences, expression systems, and methods of use
CN109811008A (zh) CRISPR-Cas9系统介导的小鼠FGF5基因敲除的方法
CN114621929B (zh) 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用
CN115125270A (zh) 一种α-珠蛋白过表达载体及其应用
CN115261409A (zh) 新型溶瘤腺病毒载体、由其包装的病毒及其应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead